MetaCap

Kura Oncology (KURA) vs Nuvectis Pharma (NVCT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Nuvectis Pharma (NVCT) has outperformed Kura Oncology (KURA) over the past year, gaining 218.9% versus a loss of 38.1%. Nuvectis Pharma is the larger company by market cap ($666.8 million vs $634.9 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

KURA-38.14%NVCT+218.91%
+390%+165%-60%
Nov 21, 20251 yearNov 20, 2026
KURA-45.38%NVCT+496.62%
+776%+340%-96%
Jan 31, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

KURA versus NVCT key metrics
MetricKURANVCT
Share price$6.91$19.39
Market cap$634.88M$666.80M
1-day change-5.99%-2.27%
YTD return-33.49%+156.82%
1-year return-38.14%+218.91%
5-year return-50.66%—
EPS (TTM)$-3.30$-2.00
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$67.48M—
Revenue growth (YoY)+25.24%—
Net income (latest FY)$-278.67M$-26.44M
Operating margin-449.94%—
Net margin-412.95%—
52-week high$13.90$29.28
52-week low$6.75$5.77
Distance from 52-week high-50.29%-33.77%
Analyst consensusstrong_buynone
Avg. price target upside+357.60%+82.57%
Average volume2.10M206.37K
Shares outstanding91.88M34.39M
Employees26019
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • NVCT has outperformed KURA by 257.1 percentage points over the past year.

About Kura Oncology

KURA stock →

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors.

Health Care · Biotechnology: Pharmaceutical Preparations · 260 employees

About Nuvectis Pharma

NVCT stock →

Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors.

Health Care · Biotechnology: Pharmaceutical Preparations · 19 employees

KURA vs NVCT FAQ

Which is bigger, Kura Oncology or Nuvectis Pharma?

Nuvectis Pharma (NVCT) is larger, with a market capitalization of $666.80M compared with $634.88M for Kura Oncology (KURA).

Which stock has performed better over the past year, KURA or NVCT?

NVCT returned +218.91% over the past 12 months, compared with -38.14% for KURA (price return, excluding dividends). Past performance does not predict future results.

Are Kura Oncology and Nuvectis Pharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons